Compositions and methods for prevention and treatment of hearing loss
AssigneeSt. Jude Children's Research Hospital
InventorsJian Zuo, Fei Zheng, Tetsuji Yamashita, Zoe Kellard, Tal Teitz, Jaeki Min, Taosheng Chen
Life of this patent
Estimating the term…
Abstract
Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.
Claims8
A method for treating cisplatin-induced hearing loss comprising administering to an animal, in conjunction with cisplatin, an inhibitor of epidermal growth factor receptor (EGFR) signaling, wherein the hearing loss is associated with ototoxicity, wherein the inhibitor of EGFR signaling is selected from the group consisting of mubritinib, SNS314, dabrafenib and crenolanib.
A transtympanic pharmaceutical composition in unit dosage form comprising an inhibitor of epidermal growth factor receptor (EGFR) signaling, wherein the inhibitor of EGFR signaling is selected from the group consisting of mubritinib, SNS314, dabrafenib and crenolanib, characterized in that each unit of the pharmaceutical composition is between 100 μl and 900 μl.
A pharmaceutical composition comprising an inhibitor of epidermal growth factor receptor (EGFR) signaling and one or more regenerative agents, wherein the inhibitor of EGFR signaling is selected from the group consisting of mubritinib, SNS314, dabrafenib and crenolanib.
A method for treating cisplatin-induced hair cell loss in an ear comprising administering to a mammal an inhibitor of EGFR signaling, wherein the inhibitor of EGFR signaling is selected from the group consisting of mubritinib, SNS314, dabrafenib and crenolanib.
A method for reducing the risk of cisplatin-induced hearing loss comprising administering to an animal, in conjunction with cisplatin, an inhibitor of epidermal growth factor receptor (EGFR) signaling, wherein the hearing loss is associated with ototoxicity, wherein the inhibitor of EGFR signaling is selected from the group consisting of mubritinib, SNS314, dabrafenib and crenolanib.
A method for reducing the risk of cisplatin-induced hair cell loss in an ear comprising administering to a mammal an inhibitor of EGFR signaling, wherein the inhibitor of EGFR signaling is selected from the group consisting of mubritinib, SNS314, dabrafenib and crenolanib.
Dependencies are inferred from the claim text.